Oral Treatment for Uncomplicated Gonorrhea
For uncomplicated urogenital gonorrhea in adults without cephalosporin allergy, oral cefixime 400-800 mg as a single dose is an effective alternative to intramuscular ceftriaxone, though it is no longer first-line therapy due to current CDC recommendations favoring injectable ceftriaxone.
Current Treatment Landscape
The treatment of gonorrhea has evolved significantly due to antimicrobial resistance patterns. While oral options exist, injectable ceftriaxone 500 mg IM remains the preferred first-line treatment 1. However, when injectable therapy is not feasible, oral alternatives can be considered with important caveats.
Oral Cefixime: Efficacy by Anatomic Site
Urogenital Infections
- Cefixime 400 mg single oral dose demonstrates 97% cure rate for uncomplicated urogenital gonorrhea 2
- Cefixime 800 mg single oral dose shows 98% cure rate for urogenital sites 2
- Historical studies confirmed cefixime 400 mg was non-inferior to ceftriaxone 250 mg IM for urogenital infections, with cure rates of 96-98% 3, 4
Rectal Infections
- Cefixime 400 mg achieves 97% cure rate for rectal gonorrhea, though data are more limited 2
- Recent evidence confirms high efficacy for urogenital and rectal sites when pharyngeal infection is excluded 5
Pharyngeal Infections: Critical Limitation
- Cefixime performs significantly worse for pharyngeal gonorrhea, with only 89% cure rate at 400 mg and 81% at 800 mg 2
- This is a major clinical pitfall, as pharyngeal infections are often asymptomatic and concurrent with urogenital infection 6
- A 2024 study showed all treatment failures with cefixime occurred at pharyngeal sites 5
- Higher ceftriaxone doses (up to 3 g) may be needed for pharyngeal infections with elevated MICs 6
Practical Clinical Algorithm
When considering oral cefixime:
- Screen for pharyngeal exposure - Ask about oral sexual contact
- Test pharyngeal site if any oral exposure - Do not rely on symptoms alone
- If pharyngeal infection present or suspected: Use injectable ceftriaxone, NOT oral cefixime 5, 2
- If confirmed urogenital/rectal only: Cefixime 400 mg oral single dose is acceptable 6, 2
Emerging Oral Alternatives
Gepotidacin (Novel Agent)
- Oral gepotidacin (two 3000 mg doses 10-12 hours apart) demonstrated non-inferiority to ceftriaxone plus azithromycin for urogenital gonorrhea 7
- Achieved 92.6% microbiological success rate in phase 3 trials 7
- Represents a promising future oral option, though not yet FDA-approved for routine use
Gentamicin Plus Azithromycin
- Intramuscular gentamicin 240 mg plus oral azithromycin 2 g is effective for extragenital azithromycin-susceptible infections 6
- However, azithromycin resistance varies substantially by region (4-66%), limiting utility 6
Critical Caveats and Pitfalls
Avoid these common errors:
- Never use quinolones (ciprofloxacin, ofloxacin, levofloxacin) - While historically recommended 6, widespread resistance now makes these obsolete for gonorrhea treatment
- Do not assume urogenital-only infection - Always assess for pharyngeal and rectal exposure through sexual history
- Concurrent chlamydia treatment is essential - Add doxycycline 100 mg twice daily for 7 days if chlamydia not excluded 1
- Test of cure is mandatory when using oral therapy, particularly for pharyngeal sites 8
Resistance Monitoring
Recent data from Vietnam showed that while all follow-up cultures were negative after cefixime 800 mg, NAAT positivity was higher (45%) compared to ceftriaxone (17.7%), particularly at pharyngeal sites 8. This may reflect slower bacterial clearance or detection of nonviable organisms, but underscores the importance of culture-based test of cure when available 8.
The bottom line: Oral cefixime 400 mg is acceptable for confirmed urogenital or rectal gonorrhea only, but injectable ceftriaxone remains superior and should be used whenever pharyngeal infection cannot be excluded.